Featured Publications
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal Of Psychiatry 2021, 178: 352-362. PMID: 33653121, DOI: 10.1176/appi.ajp.2020.20010018.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusionEfficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer J, Landeros-Weisenberger A, Johnson J, Londono Tobon A, Flores J, Nasir M, Couloures K, Sanacora G, Bloch M. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2022, 20: 241-251. PMID: 37153136, PMCID: PMC10153503, DOI: 10.1176/appi.focus.22020004.Peer-Reviewed Original ResearchTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusion
2024
Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2024, 34: 73-79. PMID: 38170185, PMCID: PMC11262580, DOI: 10.1089/cap.2023.0047.Peer-Reviewed Original ResearchDepression symptom improvementTreatment-resistant depressionChildren's Depression Rating ScaleReuptake inhibitor medicationsDepression Rating ScaleSymptom improvementAntidepressant responseInhibitor medicationKetamine responseAdolescent treatment-resistant depressionRapid-acting antidepressant agentsSelective serotonin reuptake inhibitor medicationsSerotonin reuptake inhibitor medicationsKetamine’s antidepressant responseCurrent depressive episodeSevere depressive symptomsGreater symptom improvementAttention-deficit/hyperactivity disorder diagnosisFuture therapeutic useAntidepressant medicationMedication trialsCrossover trialAntidepressant agentsClinical variablesDepressive episode